26.08.2021 • News

Lukoil Starts Work on Perm Propylene Plant

Russian oil and petrochemicals group Lukoil has started building a catalytic cracking complex at its Perm refinery. The complex includes a catalytic cracking unit producing propylene, a high-octane gasoline components unit and infrastructure facilities. Feedstock capacity will be 1.8 million t/y with production scheduled to launch in 2026.

Lukoil said a distinctive feature of the complex will be its highly adjustable propylene yield. The facility will produce polymer-grade propylene to be used as feedstock for Lukoil’s petrochemical plants. Propylene capacity was not disclosed.

The Russian firm said the project is being implemented under an agreement with the Russian energy ministry that is providing an investment incentive as part of the recent introduction of a negative excise tax on refinery feedstock until Jan. 1, 2031.

On Jul. 22, Lukoil broke ground on a PP project in Nizhny Novgorod. The company said the 500,000 t/y plant will be Russia’s largest PP facility. It did not specify when the facility is due to go on stream.

Author: Elaine Burridge, Freelance Journalist

Russia’s Lukoil has started building a catalytic cracking complex at its Perm...
Russia’s Lukoil has started building a catalytic cracking complex at its Perm refinery. The complex includes a polymer-grade propylene plant, with highly adjustable yield, to be used as feedstock for Lukoil’s petrochemical plants. Production is scheduled to start in 2026. (c) Lukoil

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read